Aurora Cannabis (ACB) Debt to Equity (2018 - 2025)

Aurora Cannabis (ACB) reported Debt to Equity of $0.01 for Q4 2025, down 34.94% quarter-over-quarter from $0.01 in Q3 2025.

Aurora Cannabis (ACB) Debt to Equity (2018 - 2025) Analysis & Trends

Aurora Cannabis (ACB) has 8 years of Debt to Equity data on file, last reported at $0.01 in Q4 2025.

Debt to Equity for Q4 2025 came in at $0.01, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $0.01 (changed N/A YoY), and the FY2025 annual result was $0.08, down 57.29% from the prior year.
Debt to Equity fell to $0.01 in Q4 2025 per ACB's latest filing, from $0.01 in the prior quarter.
Over five years, Debt to Equity peaked at $0.18 in Q1 2024 and troughed at $0.0 in Q2 2021.
A 5-year average of $0.05 and a median of $0.02 in 2025 frame the typical range for Debt to Equity.
The sharpest annual moves came in 2021 and 2022: Debt to Equity slumped 97.36% in 2021, then soared 9238.89% in 2022.
A 5-year view of Debt to Equity shows it stood at $0.0 in 2021, then soared by 9238.89% to $0.02 in 2022, then jumped by 325.49% to $0.09 in 2023, then soared by 88.72% to $0.18 in 2024, then slumped by 95.07% to $0.01 in 2025.
Business Quant data shows ACB's Debt to Equity at $0.01 in Q4 2025, $0.01 in Q3 2025, and $0.01 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	2.02
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	2.80
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	-
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.01
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	-
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.61
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	0.86
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.47
10	Liquidia	5.64 Bn	5.42 Bn	121.79 Mn	-

Download Data